Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.57
FGEN's Cash to Debt is ranked lower than
69% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. FGEN: 2.57 )
Ranked among companies with meaningful Cash to Debt only.
FGEN' s 10-Year Cash to Debt Range
Min: 1.27  Med: 2.33 Max: N/A
Current: 2.57
Equity to Asset 0.47
FGEN's Equity to Asset is ranked lower than
73% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. FGEN: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
FGEN' s 10-Year Equity to Asset Range
Min: -0.3  Med: 0.33 Max: 0.47
Current: 0.47
-0.3
0.47
Z-Score: 2.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -42.30
FGEN's Operating margin (%) is ranked higher than
56% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. FGEN: -42.30 )
Ranked among companies with meaningful Operating margin (%) only.
FGEN' s 10-Year Operating margin (%) Range
Min: -41.29  Med: -36.41 Max: -7.78
Current: -42.3
-41.29
-7.78
Net-margin (%) -47.66
FGEN's Net-margin (%) is ranked higher than
54% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. FGEN: -47.66 )
Ranked among companies with meaningful Net-margin (%) only.
FGEN' s 10-Year Net-margin (%) Range
Min: -49.4  Med: -43.24 Max: -14.63
Current: -47.66
-49.4
-14.63
ROE (%) -42.83
FGEN's ROE (%) is ranked lower than
57% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. FGEN: -42.83 )
Ranked among companies with meaningful ROE (%) only.
FGEN' s 10-Year ROE (%) Range
Min: -89.68  Med: -89.68 Max: -89.68
Current: -42.83
ROA (%) -18.23
FGEN's ROA (%) is ranked higher than
58% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. FGEN: -18.23 )
Ranked among companies with meaningful ROA (%) only.
FGEN' s 10-Year ROA (%) Range
Min: -15.25  Med: -10.28 Max: -5.31
Current: -18.23
-15.25
-5.31
ROC (Joel Greenblatt) (%) -51.73
FGEN's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. FGEN: -51.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -36.93  Med: -21.73 Max: -6.53
Current: -51.73
-36.93
-6.53
» FGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

FGEN Guru Trades in

FGEN Guru Trades in

Q1 2015

FGEN Guru Trades in Q1 2015

Joel Greenblatt 40,955 sh (New)
» More
Q2 2015

FGEN Guru Trades in Q2 2015

Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.42
FGEN's P/B is ranked lower than
63% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. FGEN: 5.42 )
Ranked among companies with meaningful P/B only.
FGEN' s 10-Year P/B Range
Min: 4.36  Med: 7.33 Max: 9.95
Current: 5.42
4.36
9.95
P/S 2.56
FGEN's P/S is ranked higher than
58% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. FGEN: 2.56 )
Ranked among companies with meaningful P/S only.
FGEN' s 10-Year P/S Range
Min: 2.58  Med: 20.24 Max: 31.06
Current: 2.56
2.58
31.06
Current Ratio 4.15
FGEN's Current Ratio is ranked higher than
50% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. FGEN: 4.15 )
Ranked among companies with meaningful Current Ratio only.
FGEN' s 10-Year Current Ratio Range
Min: 2.88  Med: 3.79 Max: 4.51
Current: 4.15
2.88
4.51
Quick Ratio 4.15
FGEN's Quick Ratio is ranked higher than
52% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. FGEN: 4.15 )
Ranked among companies with meaningful Quick Ratio only.
FGEN' s 10-Year Quick Ratio Range
Min: 2.88  Med: 3.79 Max: 4.51
Current: 4.15
2.88
4.51
Days Sales Outstanding 26.69
FGEN's Days Sales Outstanding is ranked higher than
79% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. FGEN: 26.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
FGEN' s 10-Year Days Sales Outstanding Range
Min: 22.33  Med: 41.02 Max: 48.63
Current: 26.69
22.33
48.63

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.60
FGEN's Price/Tangible Book is ranked lower than
53% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. FGEN: 5.60 )
Ranked among companies with meaningful Price/Tangible Book only.
FGEN' s 10-Year Price/Tangible Book Range
Min: 5.6  Med: 7.29 Max: 10.09
Current: 5.6
5.6
10.09
Price/Median PS Value 0.37
FGEN's Price/Median PS Value is ranked higher than
89% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. FGEN: 0.37 )
Ranked among companies with meaningful Price/Median PS Value only.
FGEN' s 10-Year Price/Median PS Value Range
Min: 0.37  Med: 1.10 Max: 1.2
Current: 0.37
0.37
1.2
Earnings Yield (Greenblatt) (%) -5.44
FGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
54% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. FGEN: -5.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FGEN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -7.5  Med: 0.00 Max: 0
Current: -5.44
-7.5
0

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 194 158 190 141
EPS($) -1.51 -1.75 -1.75 -2.89
EPS without NRI($) -1.51 -1.75 -1.75 -2.89

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:FGEN.Mexico, 1FG.Germany,
FibroGen Inc was incorporated in 1993 in Delaware. It is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The Company's focus in the areas of fibrosis and hypoxia-inducible factor biology has generated multiple programs targeting various therapeutic areas. Its product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases ("HIF-PHs"), in Phase 3 clinical development for the treatment of anemia in chronic kidney disease ("CKD"). FG-3019 is the Company's monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis ("IPF"), pancreatic cancer and liver fibrosis. The Company's business area includes Europe and Japan. Certain of the components of its product candidates are acquired from single-source suppliers and have been purchased without long-term supply agreements. The Comapny do not have an alternative supplier of certain components of their product candidates. The Company faces competition from multiple other pharmaceutical and biotechnology companies, many of which have greater financial, technical and human resources and experience in product development, manufacturing and marketing. Its trademarks include "FibroGen". The clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and marketing, among other things, of its product candidates are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for FGEN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
FIBROGEN INC Financials Aug 27 2015
PRESS STATEMENT: First Gen reports 1H 2015 attributable net income at US.3 million Aug 19 2015
Edited Transcript of FGEN earnings conference call or presentation 13-Aug-15 8:30pm GMT Aug 17 2015
FibroGen Inc Earnings Call scheduled for 4:30 pm ET today Aug 13 2015
FibroGen Announces Second Quarter 2015 Financial Results Aug 13 2015
FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 13 2015
FibroGen Announces Second Quarter 2015 Financial Results Aug 13 2015
Why Akebia Therapeutics Is Worth $10 Per Share, But Needs More Visibility Aug 13 2015
Q2 2015 FibroGen Inc Earnings Release - After Market Close Aug 13 2015
Nephrology Dialysis Transplantation Reports Phase 2 Data of Investigational Orally Active HIF-PHI... Aug 12 2015
Nephrology Dialysis Transplantation Reports Phase 2 Data of Investigational Orally Active HIF-PHI... Aug 12 2015
FIBROGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Aug 12 2015
Can Immune Design (IMDZ) Surprise This Earnings Season? Aug 10 2015
CyberArk Software (CYBR) Q2 Earnings: What's in Store? Aug 10 2015
Why FibroGen (FGEN) Might Surprise This Earnings Season - Tale of the Tape Aug 10 2015
FibroGen to Report Second Quarter 2015 Financial Results on August 13, 2015 Aug 10 2015
FibroGen to Report Second Quarter 2015 Financial Results on August 13, 2015 Aug 10 2015
It's getting 'bloody' for biotech stocks Aug 10 2015
FibroGen Appoints Jeffrey W. Henderson to Board of Directors Aug 06 2015
FibroGen Appoints Jeffrey W. Henderson to Board of Directors Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK